⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Pharmanovia and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Pharmanovia
↗Basildon, United Kingdom
Pharmanovia is a global specialty pharmaceutical company that focuses on the lifecycle management of established medicines. The company revitalizes, extends, and expands the utility of iconic pharmaceutical brands through rediscovery, repurposing, and re-engineering, while also commercializing novel pharmaceuticals.
Operating in over 160 markets, Pharmanovia manages a diverse portfolio of more than 25 brands across four core therapeutic areas: Endocrinology, Neurology, Cardiovascular, and Oncology. The company utilizes an asset-light business model, often acquiring established brands from larger pharmaceutical companies or in-licensing specialty products to drive growth and improve patient access.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals
SIZE & FINANCIALS
Employees:201-500
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Owned
Total Raised:$2.26B
Investors:Triton Partners
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb
Active Trials:2
Trial Phases:-
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Pharmanovia A/S, Atnahs Pharma Nordics A/S
Key Partnerships:Lindis Biotech (Catumaxomab licensing), Aquestive Therapeutics (Libervant licensing), Sanofi (CNS portfolio acquisition), CSL Seqirus (Parkinson's treatment rights)
COMPETITION
Position:Niche Player
Competitors:Morningside Pharmaceuticals, Brown & Burk
LEADERSHIP
Key Executives:
Stephan Eder - CEO
LINKS
Website:pharmanovia.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pharmanovia. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.